Timothé Ménard

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Machine Learning

Artificial Intelligence

Top Venues

Therapeutic innovation & regulatory science

JCO precision oncology

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Björn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, Frederik Collin, Annett Keller, Michaela Mattheus, Ioannis Spyroglou, Sandra Donevska, Timothé Ménard, null null
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium. Therapeutic innovation & regulatory science 58 (4) (2024)
Katrina Andrea Bramstedt, Timothé Ménard
Adaptive Machine Learning Systems in Medicine: The Post-Authorization Phase. The American journal of bioethics : AJOB 24 (10) (2024)
Björn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, Frederik Collin, Annett Keller, Michaela Mattheus, Ioannis Spyroglou, Sandra Donevska, Timothé Ménard, null null
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium. Therapeutic innovation & regulatory science 58 (4) (2024)
Björn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, Frederik Collin, Annett Keller, Michaela Mattheus, Ioannis Spyroglou, Sandra Donevska, Timothé Ménard, null null
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium. Therapeutic innovation & regulatory science (2024)
Björn Koneswarakantha, Ronojit Adyanthaya, Jennifer Emerson, Frederik Collin, Annett Keller, Michaela Mattheus, Ioannis Spyroglou, Sandra Donevska, Timothé Ménard, null null
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium. Therapeutic innovation & regulatory science 58 (4) (2024)
Timothé Ménard
Good quality practices for artificial intelligence in genetics. European journal of human genetics : EJHG 30 (9) (2022)
Timothé Ménard
Advanced analytics for clinical trial quality: Commentary on 'Can quality management drive evidence generation?' Clinical trials (London, England) 19 (3) (2022)
Björn Koneswarakantha, Timothé Ménard
Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing. Therapeutic innovation & regulatory science 56 (3) (2022)
Timothé Ménard
Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing-A Quality Assurance Strategy. JCO precision oncology 6 (2022)
Timothé Ménard, Kyle Young, Laura Siegel, Jennifer Emerson, Robert Studt, Leslie Sidor, null null
Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group. CPT: pharmacometrics & systems pharmacology 10 (8) (2021)
Yves Barmaz, Timothé Ménard
Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials. Drug safety 44 (9) (2021)
Timothé Ménard, Alaina Barros, Christopher Ganter
Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development. Therapeutic innovation & regulatory science 55 (5) (2021)
Timothé Ménard
Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19. Therapeutic innovation & regulatory science 55 (3) (2021)
Timothé Ménard, Donato Rolo, Björn Koneswarakantha
Clinical Quality in Cancer Research: Strategy to Assess Data Integrity of Germline Variants Inferred from Tumor-Only Testing Sequencing Data. Pharmaceutical medicine 35 (4) (2021)
Björn Koneswarakantha, Timothé Ménard
Open Source Analytics App for Clinical Trials: Letter to the Editor-A Novel App for Insights into Laboratory Data of Clinical Trials. Therapeutic innovation & regulatory science 55 (6) (2021)
Timothé Ménard, Björn Koneswarakantha, Donato Rolo, Yves Barmaz, Leszek Popko, Rich Bowling
Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials? Drug safety 43 (3) (2020)
Timothé Ménard, Yves Barmaz, Björn Koneswarakantha, Rich Bowling, Leszek Popko
Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning. Drug safety 42 (9) (2020)
Min Zou, Yves Barmaz, Melissa Preovolos, Leszek Popko, Timothé Ménard
Using Statistical Modeling for Enhanced and Flexible Pharmacovigilance Audit Risk Assessment and Planning. Therapeutic innovation & regulatory science 55 (1) (2020)
Björn Koneswarakantha, Yves Barmaz, Timothé Ménard, Donato Rolo
Follow-up on the Use of Advanced Analytics for Clinical Quality Assurance: Bootstrap Resampling to Enhance Detection of Adverse Event Under-Reporting. Drug safety 44 (1) (2020)